- Home
- IOVA vs RUN Comparison
IOVA vs RUN Comparison
Compare IOVA & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- RUN
- Stock Information
- Founded
- IOVA 2007
- RUN 2007
- Country
- IOVA United States
- RUN United States
- Employees
- IOVA N/A
- RUN N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- RUN Industrial Machinery/Components
- Sector
- IOVA Health Care
- RUN Miscellaneous
- Exchange
- IOVA Nasdaq
- RUN Nasdaq
- Market Cap
- IOVA 2.6B
- RUN 2.2B
- IPO Year
- IOVA N/A
- RUN 2015
- Fundamental
- Price
- IOVA $5.82
- RUN $8.26
- Analyst Decision
- IOVA Strong Buy
- RUN Buy
- Analyst Count
- IOVA 9
- RUN 21
- Target Price
- IOVA $23.06
- RUN $18.86
- AVG Volume (30 Days)
- IOVA 7.2M
- RUN 9.5M
- Earning Date
- IOVA 02-26-2025
- RUN 02-27-2025
- Dividend Yield
- IOVA N/A
- RUN N/A
- EPS Growth
- IOVA N/A
- RUN N/A
- EPS
- IOVA N/A
- RUN N/A
- Revenue
- IOVA $90,858,000.00
- RUN $2,035,817,000.00
- Revenue This Year
- IOVA $13,803.28
- RUN N/A
- Revenue Next Year
- IOVA $167.55
- RUN $12.75
- P/E Ratio
- IOVA N/A
- RUN N/A
- Revenue Growth
- IOVA 12751.20
- RUN N/A
- 52 Week Low
- IOVA $5.05
- RUN $7.87
- 52 Week High
- IOVA $18.33
- RUN $22.26
- Technical
- Relative Strength Index (RSI)
- IOVA 49.38
- RUN 44.64
- Support Level
- IOVA $5.44
- RUN $8.32
- Resistance Level
- IOVA $5.80
- RUN $9.31
- Average True Range (ATR)
- IOVA 0.31
- RUN 0.50
- MACD
- IOVA 0.09
- RUN 0.06
- Stochastic Oscillator
- IOVA 82.43
- RUN 55.20
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About RUN Sunrun Inc.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed either by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.